Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,621 signal articles · 208 in last 24h · 133,892 total before filter · latest 1h ago
208last 24h
1081last 7d
166● bullish (7d)
127● bearish (7d)
208publishers
AllMacro285Earnings363M&A73Regulatory28Product10Analyst16
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
How Verizon’s Q2 Results, Dark-Fiber Deal With Google And Raised Outlook At Verizon (VZ) Has Changed Its Investment Story
Simply Wall St.41d agoneutral
How Verizon’s Q2 Results, Dark-Fiber Deal With Google And Raised Outlook At Verizon (VZ) Has Changed Its Investment Story

Verizon Communications has reported its second-quarter 2026 results, with revenue of US$34,253 million and net income of US$3,835 million, while also completing US$3,500 million of share repurchases under its January 2026 buyback program. Alongside the earnings release, Verizon unveiled a dark-fiber deal with Google worth more than US$1 billion and raised its 2026 outlook for adjusted earnings, free cash flow and share repurchases, pointing to growing emphasis on AI infrastructure...

AMD price target boosted on strengthening AI outlook
Proactive41d agoneutral
AMD price target boosted on strengthening AI outlook

Advanced Micro Devices Inc (NASDAQ:AMD, XETRA:AMD) saw its price target raised to $600 from $450 by Wedbush following the chipmaker’s Advancing AI 2026 event, with the analysts writing that new partnerships and improving supply chain conditions increased confidence in the company’s data center...

Investing.com41d agobearish
JPMorgan cuts Rollins to Neutral on demand uncertainty, slashes price target

Investing.com -- JPMorgan downgraded Rollins to Neutral from Overweight and cut its price target to $45 from $70, saying uncertainty around weakening residential demand and a slower-than-expected margin recovery has made the pest control company's near-term risk-reward less compelling despite its intact long-term growth story.

WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook
StockStory41d agobullish
WST Q2 Deep Dive: Biologics and High-Value Components Drive Upgraded Outlook

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

Investing.com42d agobullish
Wolfe upgrades AT&T to Outperform as improving fundamentals outweigh Starlink risk

Investing.com -- AT&T was upgraded to Outperform from Peer Perform by Wolfe Research, which said the telecom giant's improving operating fundamentals and attractive valuation more than offset lingering concerns over competition from SpaceX's Starlink mobile ambitions. The brokerage assigned a $29 price target, implying nearly 26% upside from the stock's recent close.